Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 99710.49%.

  • Crinetics Pharmaceuticals' EBIT Margin changed N/A to 99710.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 31130.16%, marking a year-over-year decrease of 16049500.0%. This contributed to the annual value of 32613.47% for FY2024, which is 270663000.0% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBIT Margin is 99710.49%.
  • Crinetics Pharmaceuticals' 5-year EBIT Margin high stood at 1080.39% for Q1 2022, and its period low was 99710.49% during Q3 2025.
  • For the 5-year period, Crinetics Pharmaceuticals' EBIT Margin averaged around 17652.03%, with its median value being 9805.24% (2022).
  • Data for Crinetics Pharmaceuticals' EBIT Margin shows a peak YoY increase of 82246300bps (in 2025) and a maximum YoY decrease of -193712000bps (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' EBIT Margin stood at 2865.31% in 2021, then plummeted by -134bps to 6707.48% in 2022, then tumbled by -154bps to 17045.38% in 2023, then fell by -22bps to 20747.62% in 2024, then crashed by -381bps to 99710.49% in 2025.
  • Its last three reported values are 99710.49% in Q3 2025, 12522.99% for Q2 2025, and 30860.11% during Q1 2025.